Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Teva Pharmaceutical (TEVA) has shared an announcement.
Teva Pharmaceutical Industries Ltd. is undergoing a major executive shift as Mr. Eric Drapé steps down from his role as Executive Vice President, Global Operations, to be succeeded by Mr. Matthew Shields on June 3, 2024. Shields brings over 25 years of experience in biopharmaceuticals and animal health industries, having held significant positions at Merck Animal Health and Sanofi. His compensation package includes a base salary of $825,000, potential annual cash incentives, equity awards, and substantial severance benefits, positioning him as a key player in Teva’s future operations.
For an in-depth examination of TEVA stock, go to TipRanks’ Stock Analysis page.
